Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
953 Views
eMediNexus 17 January 2018
A study was performed to determine whether canagliflozin can reduce the thickness of epicardial adipose tissue, that is associated with insulin resistance and is a risk factor for coronary artery disease. The results published in the Diabetology and Metabolic Syndrome journal showed that this drug decreased the epicardial adipose tissue thickness in patients with type 2 diabetes mellitus (from 9.3 ± 2.5 to 7.3 ± 2.0 mm). This effect is independent of its impact on lowering blood glucose, indicating that canagliflozin may be helpful in preventing cardiovascular complications in this patient population.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Nuchal Translucency Measurements in Prenatal Screening: Revisiting NT.....
Choosing the Right Fats for a Healthy Life..
Achieving Type 2 Diabetes Remission through Weight Loss: How Much is .....
Sarcopenia: A Harbinger of Cognitive Decline in Postmenopausal Women?..
Integrating Early CKD Detection into Primary Care: A Call for Action i.....
{{Article_Title}}..
Panel Recommends OPD Coverage, Extended Post-Hospitalisation Benefits under Ayushman Bharat..
Slushy Ice Drinks Pose Health Risks for Young Children, Warn Experts..
Affordable Biosimilars Indias Key to Reducing Healthcare Costs..
ICMR Study Links River Drain Pollution to Cancer Risk; Govt. Expands Cancer Care Facilities..
Spike in Seasonal Flu Cases Alarms Delhi: Survey Shows Over 50% Households Affected..
eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.
